KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Assets (2019 - 2025)

Historic Assets for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $19.6 billion.

  • Royalty Pharma's Assets rose 767.21% to $19.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $19.6 billion, marking a year-over-year increase of 767.21%. This contributed to the annual value of $19.6 billion for FY2025, which is 767.21% up from last year.
  • As of Q4 2025, Royalty Pharma's Assets stood at $19.6 billion, which was up 767.21% from $19.3 billion recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Assets registered a high of $19.6 billion during Q4 2025, and its lowest value of $15.9 billion during Q3 2023.
  • Moreover, its 5-year median value for Assets was $17.6 billion (2021), whereas its average is $17.4 billion.
  • As far as peak fluctuations go, Royalty Pharma's Assets crashed by 1028.19% in 2023, and later surged by 1379.15% in 2024.
  • Royalty Pharma's Assets (Quarter) stood at $17.5 billion in 2021, then dropped by 4.01% to $16.8 billion in 2022, then decreased by 2.57% to $16.4 billion in 2023, then grew by 11.24% to $18.2 billion in 2024, then grew by 7.67% to $19.6 billion in 2025.
  • Its last three reported values are $19.6 billion in Q4 2025, $19.3 billion for Q3 2025, and $18.3 billion during Q2 2025.